title: Forging a modern generation of polyphenol-based therapeutics.
abstract: The long-standing debate that polyphenol secondary metabolites from dietary plants are important nutritional components continues due to compelling evidence for their abilities to ameliorate degenerative conditions including, cancer, neurological disorders and cardiovascular disease. The clinical use of polyphenols is not, however, mainstream as issues regarding poor selectivity, dosage, toxicity and delivery methods are unresolved. The paper by Rieder et al. suggests that the lack of selectivity, at least for the stilbene, resveratrol, may not be a major limiting factor. The present commentary is a critique of this significant finding that is focused on deciding how the use of resveratrol as clinical medicine could be advanced, and how this new information integrates with current knowledge of polyphenol physiological effects. This commentary suggests that the multi-target nature of polyphenols may be translated into reliable therapy using the current systems/network pharmacology approach concerned with developing viable therapeutic agents that achieve specific effects through interactions with a wide array of targets.
  
  
  BACKGROUND
  This article is a commentary on Rieder et al., pp. 1244-1258 of BJP 167:6. To view this paper visit http://dx.doi.org/10.1111/j.1476-5381.2012.02063.x.
authors.affiliation: School of Pharmacy, University of Reading, Reading, UK. b.wright@reading.ac.uk
authors.forename: Bernice
authors.initials: B
authors.lastname: Wright
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D004768:Enterotoxins / Q000008:administration & dosage*; D005260:Female; D055370:Lung Injury / Q000188:drug therapy*; D011014:Pneumonia / Q000188:drug therapy*; D013267:Stilbenes / Q000627:therapeutic use*
chemical_list: D000893:Anti-Inflammatory Agents; D004768:Enterotoxins; D013267:Stilbenes